CRISPR Therapeutics (CRSP) CEO Samarth Sells $202K of Stock

Samarth Kulkarni, Chief Executive Officer of CRISPR Therapeutics AG (NasdaqGM: CRSP), sold 4,098 shares on October 14, 2026, at a price of $49.26 each. This transaction brought in approximately $201,867. Kulkarni's sale comes as the stock has been trading below its short and long-term moving averages, indicating potential weakness in its price performance.

Inside Kulkarni's Trade

Kulkarni's sale of 4,098 shares is not part of a planned transaction, and it reflects his decision to reduce his holdings at a time when the stock is facing downward pressure. The shares sold were at a price of $49.26, which is below the recent trading levels.

Other Institutional Activity in CRISPR Therapeutics

Several other institutional investors have recently adjusted their positions in CRISPR Therapeutics. Blackrock Inc. added 668,932 shares, raising its total to 8,348,977 shares valued at about $411.2 million. Meanwhile, ARK Investment Management, LLC reduced its stake by 1,853,267 shares, bringing its holdings down to 9,460,939 shares worth approximately $466 million. Orbis Allan Gray Ltd also trimmed its position by 657,026 shares, ending with 5,449,161 shares valued at around $268.4 million. Additionally, State Street Corporation increased its holdings slightly by 339,298 shares, totaling 4,321,666 shares worth about $212.8 million.

CRISPR Therapeutics AG Stock Down 1.0%

Currently, CRISPR Therapeutics shares are trading around $50.98 as of October 16, 2026. This price is about 7.3% below the 50-day moving average of $54.99 and 4.1% below the 200-day average of $53.13. The stock is also down approximately 32.1% from its 52-week high of $75.06, but it remains 15.5% above its 52-week low of $44.12.

Recent Earnings

CRISPR Therapeutics reported trailing twelve-month revenue of approximately $13.4 million, reflecting a remarkable year-over-year growth of 1,041.4%. However, the company reported a net margin of 0.0% and a negative return on equity (ROE) of -26.1%. The next earnings report is expected on November 9, 2026.

Insider Buying and Selling at CRISPR Therapeutics AG

In addition to Kulkarni's recent sale, other insiders have also been active. On October 14, 2026, General Counsel James R. Kasinger sold 1,040 shares at $49.26, totaling about $51,230. Earlier in September, Kasinger sold 10,400 shares for $626,460, and another 1,990 shares for $119,481. Director Ali Behbahani sold 13,679 shares on September 17 for $780,935.

Analysts Set New Price Targets

On July 8, 2026, HC Wainwright & Co. reiterated a "Buy" rating with a price target of $80. Citigroup maintained a "Buy" rating on August 4, 2026, with a target of $88, up from $82. Citizens also reiterated a "Market Outperform" rating with a price target of $80 on August 25, 2026. The consensus recommendation for CRISPR Therapeutics is currently a "Buy" with a mean price target of approximately $85.63 from 19 analyst opinions.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland. It focuses on developing gene-based medicines for serious human diseases using its CRISPR/Cas9 gene-editing technology. This innovative approach allows for precise alterations of genomic DNA, positioning the company at the forefront of genetic medicine.

Bottom Line

As CRISPR Therapeutics prepares for its upcoming earnings report on November 9, 2026, investors will be watching for any changes in performance amid recent insider selling. Kulkarni's sale, along with other institutional movements, reflects the current sentiment surrounding the stock's challenges in the market.